Exelixis Sees Unusually High Options Volume (EXEL)

Exelixis, Inc. (NASDAQ:EXEL) was the target of unusually large options trading activity on Monday. Investors bought 7,218 call options on the stock. This is an increase of approximately 585% compared to the average daily volume of 1,054 call options.

In related news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the completion of the sale, the director now owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.10% of the company’s stock.

Several large investors have recently modified their holdings of the company. FMR LLC raised its position in shares of Exelixis by 2.0% in the 2nd quarter. FMR LLC now owns 43,748,695 shares of the biotechnology company’s stock valued at $1,077,530,000 after buying an additional 857,452 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Exelixis by 7.2% in the 2nd quarter. Vanguard Group Inc. now owns 25,441,964 shares of the biotechnology company’s stock valued at $626,635,000 after buying an additional 1,706,893 shares in the last quarter. Matrix Capital Management Company LP raised its position in shares of Exelixis by 8.8% in the 2nd quarter. Matrix Capital Management Company LP now owns 15,117,460 shares of the biotechnology company’s stock valued at $372,343,000 after buying an additional 1,225,000 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Exelixis by 13.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 7,059,232 shares of the biotechnology company’s stock valued at $173,869,000 after buying an additional 818,782 shares in the last quarter. Finally, Old Mutual Global Investors UK Ltd. raised its position in shares of Exelixis by 3.1% in the 2nd quarter. Old Mutual Global Investors UK Ltd. now owns 5,196,829 shares of the biotechnology company’s stock valued at $127,997,000 after buying an additional 155,569 shares in the last quarter. Institutional investors own 81.15% of the company’s stock.

Several analysts have weighed in on EXEL shares. Leerink Swann cut shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $34.00 to $28.00 in a research note on Friday, September 22nd. Oppenheimer reiterated a “hold” rating on shares of Exelixis in a research note on Monday, September 25th. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price objective on shares of Exelixis in a research note on Monday, October 2nd. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a research note on Tuesday, October 10th. Finally, Cann reiterated a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $32.13.

Exelixis (NASDAQ EXEL) opened at $30.38 on Friday. The company has a market cap of $8,990.00, a P/E ratio of 62.00, a PEG ratio of 0.90 and a beta of 1.88. Exelixis has a 12-month low of $16.72 and a 12-month high of $32.50.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.08 by $0.18. The company had revenue of $152.50 million during the quarter, compared to analysts’ expectations of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business’s revenue for the quarter was up 145.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.04) EPS. equities research analysts forecast that Exelixis will post 0.49 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Exelixis Sees Unusually High Options Volume (EXEL)” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/14/investors-purchase-large-volume-of-call-options-on-exelixis-exel-updated-updated.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply